• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

OPINIONI - Opinions

Volume:

Biochimica Clinica 2018; 42(2) 152-154

Pubblicato on-line:

May 9, 2018

DOI:

10.19186/BC_2018.030

Scarica in PDF:
Autenticazione richiesta

L’analisi dello stato di instabilità dei microsatelliti per la diagnosi e la terapia dei tumori correlati alla sindrome di Lynch

AUTORI

Francesca Duraturo1, Paola Izzo1,2
1Dipartimento di Medicina Molecolare e Biotecnologie Mediche e 2CEINGE Biotecnologie Avanzate, Università Federico II, Napoli

ABSTRACT

Detection analysis of microsatellite instability status for the diagnosis and therapy of Lynch syndrome-related cancers

Lynch syndrome (LS) is an autosomal dominant genetic disorder that is characterized by an increased risk of developing colorectal cancer. LS is associated with germline mutations in DNA mismatch repair genes (MMR) that are involved in the correction of nucleotide misalignments that may arise during DNA replication. The deficiency of the MMR complex results in a high rate of mutations in repetitive DNA sequences known as microsatellites; these, because of their structure, are more prone to errors during replication. This condition is known as microsatellite instability (MSI) and is present in about 95% of the tumors associated with LS. MSI analysis is used for making clinical diagnosis of LS. All the individuals showing MSI-high status on the tumor tissue should undergo to genetic testing to identify pathogenetic mutation in one of the MMR genes. The identification of the mutation allows making an early diagnosis, in individuals belonging to families at risk. Moreover, the MSI testing in addition to the key role in the molecular diagnosis of LS, has also a very important role in identifying the most appropriate therapeutic approach for LS patients. Recently, novel therapeutic approaches such as immunotherapy, which represent a viable alternative to traditional therapeutic methods, give a good life expectancy to patients showing a MSI-high status, who have already developed a LS-related cancer. In this paper, through a review of the most recent literature, we present this dual role of MSI analysis in Lynch syndrome.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967